Rhabdoid Tumor

• Rhabdoid Tumor is a highly aggressive and rare cancer primarily affecting very young children, often originating in the kidneys or brain.
• Symptoms vary based on tumor location but can include an abdominal mass, headaches, vomiting, and developmental delays.
• Diagnosis involves imaging, biopsy, and genetic testing, with prognosis often being challenging due to its aggressive nature.
• Treatment typically combines surgery, chemotherapy, and radiation therapy, often in intensive regimens.
• Ongoing research is exploring targeted therapies and immunotherapy to improve outcomes for affected individuals.

What is Rhabdoid Tumor? Symptoms and Causes

Rhabdoid Tumor is a highly aggressive and rare malignant neoplasm characterized by distinctive rhabdoid cells. While it can occur in various parts of the body, it is most commonly found in the kidneys (known as malignant rhabdoid tumor of the kidney, MRTK) or the brain and spinal cord (known as atypical teratoid/rhabdoid tumor, AT/RT). This cancer is particularly devastating due to its rapid growth and tendency to metastasize, primarily affecting infants and very young children, often before the age of three. Its rarity makes it a significant challenge in pediatric oncology, with an estimated incidence of less than one case per million children per year globally. (Source: National Cancer Institute).

The presentation of rhabdoid tumor symptoms causes varies significantly depending on the tumor’s primary location. For kidney tumors, a common symptom is an abdominal mass that may be felt by a parent or during a routine check-up. Other general symptoms can include:

• Abdominal pain or swelling
• Blood in the urine (hematuria)
• Fever of unknown origin
• Loss of appetite and weight loss
• Lethargy or increased irritability

When the tumor is in the brain or spinal cord (AT/RT), symptoms are neurological and may include persistent headaches, vomiting, seizures, developmental regression, or changes in behavior. The primary cause of Rhabdoid Tumor is almost always linked to a genetic mutation in the SMARCB1 gene (also known as INI1) or, less commonly, the SMARCA4 gene. These genes are tumor suppressors, meaning their normal function is to prevent uncontrolled cell growth. A mutation leads to a loss of this protective function, allowing rhabdoid cells to proliferate unchecked. In most cases, this mutation occurs spontaneously (de novo), but in a small percentage, it can be inherited from a parent, indicating a predisposition to the disease.

Rhabdoid Tumor: Diagnosis, Treatment, and Prognosis

The process of rhabdoid tumor diagnosis prognosis typically begins with imaging studies, such as ultrasound, CT scans, or MRI, to identify the tumor’s location and extent. A definitive diagnosis, however, requires a biopsy of the tumor tissue. Pathologists examine the tissue under a microscope to identify the characteristic rhabdoid cells and perform immunohistochemical staining to confirm the loss of SMARCB1 protein expression, which is a hallmark of the disease. Genetic testing is also crucial to identify mutations in the SMARCB1 or SMARCA4 genes, which not only confirms the diagnosis but can also inform treatment strategies and identify potential familial risk. The prognosis for Rhabdoid Tumor remains challenging due to its aggressive nature and tendency for early metastasis. Survival rates vary widely depending on the tumor’s location, stage at diagnosis, and the child’s age, but generally, they are lower compared to other pediatric cancers, with 5-year survival rates often reported below 50% (Source: American Cancer Society).

Effective rhabdoid tumor treatment options are aggressive and multimodal, often involving a combination of surgery, chemotherapy, and radiation therapy. The primary goal is to remove as much of the tumor as safely possible through surgical resection. Following surgery, intensive chemotherapy regimens are typically administered to target remaining cancer cells and prevent recurrence or metastasis. These regimens often involve multiple chemotherapy agents given over an extended period. Radiation therapy may also be used, especially for brain and spinal cord tumors (AT/RT), or in cases where complete surgical removal is not possible. Due to the young age of most patients, radiation therapy is carefully planned to minimize long-term developmental side effects. In some cases, high-dose chemotherapy followed by stem cell rescue may be considered. Research is ongoing to explore novel therapies, including targeted agents that specifically inhibit pathways activated by SMARCB1 deficiency, and immunotherapies, which aim to harness the body’s immune system to fight the cancer. Clinical trials offer access to these cutting-edge treatments and represent a vital option for many patients.